Overview

Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

Status:
Recruiting
Trial end date:
2023-08-22
Target enrollment:
Participant gender:
Summary
The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.
Phase:
Phase 2
Details
Lead Sponsor:
Gruppo Italiano Malattie EMatologiche dell'Adulto
Treatments:
Blinatumomab